Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 24, 2017
What are the generic sources for octreotide acetate and what is the scope of octreotide acetate freedom to operate?
Octreotide acetate is the generic ingredient in five branded drugs marketed by Novartis, West-ward Pharms Int, Sun Pharm Inds, Sagent Pharms, Fresenius Kabi Usa, Teva Pharms Usa, Wockhardt Usa, and Mylan Institutional, and is included in eighteen NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.| Tradenames: | 5 |
| Patents: | 3 |
| Applicants: | 8 |
| NDAs: | 18 |
| Drug Master File Entries: see list | 18 |
| Suppliers / Packagers: see list | 9 |
| Bulk Api Vendors: see list | 70 |
| Clinical Trials: see list | 1,078 |
| Patent Applications: see list | 6,927 |
| Therapeutic Class: | Hormonal Agents, Suppressant (Pituitary) |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see low prices |
| DailyMed Link: | octreotide acetate at DailyMed |
| Drug Class | Somatostatin Analog |
| Mechanism of Action | Somatostatin Receptor Agonists |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sagent Pharms | OCTREOTIDE ACETATE | octreotide acetate | INJECTABLE;INJECTION | 091041-002 | Nov 12, 2013 | AP | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Sun Pharm Inds | OCTREOTIDE ACETATE | octreotide acetate | INJECTABLE;INJECTION | 077373-002 | Aug 14, 2007 | AP | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-002 | Nov 25, 1998 | RX | Yes | No | ► Subscribe | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Novartis | SANDOSTATIN | octreotide acetate | INJECTABLE;INJECTION | 019667-001 | Oct 21, 1988 | AP | RX | Yes | Yes | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
West-ward Pharms Int | OCTREOTIDE ACETATE (PRESERVATIVE FREE) | octreotide acetate | INJECTABLE;INJECTION | 076313-002 | Mar 28, 2005 | AP | RX | No | Yes | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | SANDOSTATIN | octreotide acetate | INJECTABLE;INJECTION | 019667-002 | Oct 21, 1988 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-001 | Nov 25, 1998 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-002 | Nov 25, 1998 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-002 | Nov 25, 1998 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Novartis | SANDOSTATIN | octreotide acetate | INJECTABLE;INJECTION | 019667-001 | Oct 21, 1988 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia | 3234884 | ► Subscribe | |||||||||||||||||||||||||||
| Sweden | 8404225 | ► Subscribe | |||||||||||||||||||||||||||
| Greece | 80184 | ► Subscribe | |||||||||||||||||||||||||||
| Luxembourg | 85514 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 8706750 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,117 others who get our Drug Patent Expiration Alerts:
